Education
About Us
Working with TipRanks
Follow Us
Provectus Pharmaceuticals (PVCT)
OTHER OTC:PVCT
Total Valuation
Provectus Pharmaceuticals has a market cap or net worth of $36.71M. The enterprise value is ―.
Market Cap$36.71M
Enterprise Value―
Share Statistics
Provectus Pharmaceuticals has 420,279,880 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding420,279,880
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Provectus Pharmaceuticals’s return on equity (ROE) is 0.79 and return on invested capital (ROIC) is 142.91%.
Return on Equity (ROE)0.79
Return on Assets (ROA)-4.70
Return on Invested Capital (ROIC)142.91%
Return on Capital Employed (ROCE)0.66
Revenue Per Employee102.86K
Profits Per Employee-793.69K
Employee Count6
Asset Turnover0.61
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Provectus Pharmaceuticals is ―. Provectus Pharmaceuticals’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value-8.46
Price to FCF0.00
Price to Operating Cash Flow-9.96
PEG Ratio―
Income Statement
In the last 12 months, Provectus Pharmaceuticals had revenue of 617.14K and earned -4.73M in profits. Earnings per share was -0.01.
Revenue617.14K
Gross Profit609.98K
Operating Income-3.96M
Pretax Income-4.73M
Net Income-4.73M
EBITDA-4.53M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -16.62M and capital expenditures -6.14K, giving a free cash flow of -16.63M billion.
Operating Cash Flow-16.62M
Free Cash Flow-16.63M
Free Cash Flow per Share-0.04
Dividends & Yields
Provectus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.54
52-Week Price Change-10.00%
50-Day Moving Average0.08
200-Day Moving Average0.10
Relative Strength Index (RSI)59.53
Average Volume (3m)159.04K
Important Dates
Provectus Pharmaceuticals upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Provectus Pharmaceuticals as a current ratio of 0.14, with Debt / Equity ratio of -85.17%
Current Ratio0.14
Quick Ratio0.14
Debt to Market Cap0.06
Net Debt to EBITDA-0.64
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Provectus Pharmaceuticals has paid 29.59K in taxes.
Income Tax29.59K
Effective Tax Rate>-0.01
Enterprise Valuation
Provectus Pharmaceuticals EV to EBITDA ratio is -11.78, with an EV/FCF ratio of -16.23.
EV to Sales86.36
EV to EBITDA-11.78
EV to Free Cash Flow-16.23
EV to Operating Cash Flow-16.23
Balance Sheet
Provectus Pharmaceuticals has $390.44K in cash and marketable securities with ― in debt, giving a net cash position of $2.19M billion.
Cash & Marketable Securities$390.44K
Total Debt―
Net Cash$2.19M
Net Cash Per Share<$0.01
Tangible Book Value Per Share-$0.01
Margins
Gross margin is 99.00%, with operating margin of -640.81%, and net profit margin of -766.85%.
Gross Margin99.00%
Operating Margin-640.81%
Pretax Margin-766.85%
Net Profit Margin-766.85%
EBITDA Margin-733.26%
EBIT Margin-734.42%
Analyst Forecast
The average price target for Provectus Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―